The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...

GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of ...

DelveInsight's IBAT Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Glaxosmithkline, which has major operations in Montgomery County, is set to receive a major settlement, writes Anthony O. Goriainoff for the Wall Street ...

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a strong pipeline of clinical trials, and ...

The viral vector vaccines market, driven by innovation and global demand, offers expanding opportunities in immunization, notably for diseases like C ...

Investing.com -- GlaxoSmithKline (NYSE: GSK) Bioc announced its financial results for the second quarter, reporting a consolidated net profit attributable of EGP 5.9 million. The company also reported ...

It will also push ahead with plans to make innovative and modern healthcare within Asia’s reach, says its chief executive ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

GSK’s share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely ...

Assembly Biosciences is advancing its herpes drug to Phase II trials after it showed 94% antiviral efficacy in a Phase Ib ...

The FDA has agreed to fast-track its review of gepotidacin, an oral antibiotic already approved for urinary tract infections, ...